Management


Timothy P. Coleman, Ph. D., MBA

Cofounder CEO and President, Director

Tim Coleman is a chemist, biophysicist, inventor, philanthropist, and entrepreneur. He serves as the CEO of Nemucore Medical Innovations (nemucore.com) and as volunteer President of the Mending Minds Foundation (mminds.org). Tim is passionate about improving the health of people suffering from cancer and diseases of the brain. To this end he has co-founded organizations to help advance humanity’s collective ability to mitigate the harmful effects of these health conditions. His professional research efforts focus on the development of: innovative nanomedicines; immune programming platforms; a precision brain mapping system; targeted magnetic resonance imaging probes; precision small molecule therapeutics; and companion diagnostics based on system biology principles.

Tim believes many cancers are driven by the dysregulation of biology associated with non-genetic changes to a cell’s basic operating system. He is a proponent for identifying and clinical use of non-genetic changes as biomarkers that drive chemotherapeutic resistance in the battle to improve cancer outcomes. His team of precision medicine experts are developing small molecule therapeutics that use an RNA biomarker. This RNA biomarker measures the relative strength of a “network effect” of proteins involved in drug resistance and sensitivity to a key pathway responsible for malignant cell division. This system biology approach to understanding disease biology is also applicable to diseases of the brain.

Diseases of the brain including those associated with neuro-inflammation are driven by dysregulation of neuronal- or immuno-biology are one of the most sophisticated challenges of modern medicine. Today most diseases of the brain are diagnosed through clinical exclusion rather than direct molecular or cellular testing. Tim hopes to change this antiquated paradigm as he and his team are working in to develop a precision brain mapping system to accurately track diseases of the brain over time. They have developed an integrated nanomedicine brain magnetic resonance imaging system that uses paramagnetic nanoparticles to selectively bind to unique neurons in the brain. At current sensitivity, the system can map changes in a brain at the level of 20-50 cells and is designed to track structural changes in unique neurons over time. To achieve such high sensitivity, Tim and the team invented precisely targeted- paramagnetic nanoparticles that cross the blood brain barrier and tightly bind targeted neurons providing near-cellular level resolution. To analyze at this resolution, Tim and his team created an integrated data analysis software package that can analyze a single subject or be scaled to cohort level analysis. Tim is pursuing the development of the system to identify structural changes in populations of neurons to more quickly assess response to therapeutic intervention brain diseases.

Tim believes there is significant medical benefit to proactively intervening in the endocannabinoid system to mitigate diseases of the brain and peripheral nervous system. To demystify the endocannabinoid system and bring solid clinical science to the field, Tim and his team are pursuing a first ever double arm, placebo controlled, genomically-enabled, cannabinoid-based medicine clinical trial for the alleviation of chemotherapy induced peripheral neuropathy. The trial design and associated systems are being created to develop rigorous standards for testing cannabinoid-based medicines.

As an entrepreneur he enjoys the process of venture creation and has had his share of heartbreaking failures, including: BioCache Pharmaceuticals, Boston Electronic Application Market (BEAN), and Blue Ocean Biomanufacturing. True to his values, in 2018, Tim co-founded the Mending Minds Foundation to become the leading organization for the development of awareness, diagnostics, and treatments for a devastating disorder, childhood post infection neuroimmune disorders (CPIND). This neuroimmune disorder primarily affects children between the age of 3-15 and is routinely mis-diagnosed. If left untreated, it robs a child of their childhood or worse.

Always an athlete who loves to compete, Tim has become an avid runner and ultra- event competitor. He competes in 3-4 events annually using his participation to raise money for pediatric hematology oncology and breast cancer research. His personal goal is to run all six major marathons. He has authored numerous scientific papers, abstracts and patents. Tim lives in Wellesley, Massachusetts with his amazing wife, their high-energy daughter and loving dog Summer.


William S. (Sandy) White, MBA

Chief Operating Officer

William S. White is the former CEO of Icon Bioscience and has over 25 years of broad pharmaceutical industry experience, including general management, global corporate development/licensing, R&D; and technology commercialization. He previously served as Vice President of R&D;/Commercial Development & Planning at Storz Ophthalmics, a division of American Home Products; President/Business Leader of Integrated Protein Technologies, a unit of Monsanto and CEO of BioCache Pharmaceuticals, Inc. He has also served on the boards of BioCache Pharmaceuticals, CropTech Corporation (Chairman) and Nemucore Medical Innovations, Inc.


Barbara Davis, V.M.D, Ph.D.

Chief Scientific Officer

Dr. Davis is certified as a Diplomate, American College of Veterinary Pathologists and has over 20 years of research experience in female endocrine and reproductive pathology and cancers (ovarian, uterine, breast). She established and served as the Acting Chief for the first National Institutes of Health research laboratory focused on women’s health (Laboratory of Women’s Health) while at the National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC. During this time she also served as the principal investigator for the Fibroid Growth Study, (Clinical Trial Registry: www.clinicaltrials.com; Registry name: Fibroid Growth Study; NCT00340288) and responsible for study design, funding and budget, IRB approvals, coordinating sites, establishing the medical and management teams, patient recruitment, data collection, analysis and coordinating publications. Realizing the need for safe and effective therapies for cancer, Dr. Davis subsequently worked in biopharmaceutical companies involved with the development of novel anti-cancer small molecules and antibodies, working closely with our medical oncologists in efficacy studies, non-GLP and GLP toxicity studies toxicology. She is adjunct professor at Tufts University and has over 70 original research publications and book chapters.

Click Here for Selected Publications


Allison Morse, ScM, MSN, ANP-BC, WHNP, AOCNP

Director of Clinical Affairs

Allison Morse has more than 15 years of experience in the Boston area caring for women with reproductive cancers throughout the course of their disease. She has a Master’s in Public Health and a Master’s of Science in Nursing; she holds a certificate in Advanced Oncology Nursing. She has a breadth of understanding of the clinical workflow and the lived experience of women struggling to survive with multi drug resistant gynecologic cancers. In the nurse practitioner role, she collaborated on various clinical research initiatives such as early phase oncologic drug studies. In 2009, she was recognized as the Nurse Practitioner of the Year in Massachusetts by the American Academy of Nurse Practitioners.


David Williams, MS

Vice President of Manufacturing

David has over 25 years of experience in cGMP large and small molecule manufacturing operations, process development /scale-up, facility design and construction, state and local incentive development programs, and R&D.; Prior to joining NMI he was sole proprietor of TS Consulting LLC. Previous experience include senior positions at: Chlorogen, Inc., CropTech Corporation Integrated Protein Technologies (IPT) a business unit of Monsanto Company; Cephalon, Inc.; Bio Science Contract Production Corporation (which became Cambrex Bio Science); and North American Vaccine. He has also performed consultation work for the U.S. Department of State and the United Nations as UNSCOM Deputy Chief Inspector for the United Nations biological weapons inspection program in Iraq.


Nicole Stephenson, MS MBA

Director of Operations

Mrs. Stephenson coordinates the interaction of the financial and operational aspects of Nemucore. Previously Nicole worked at PricewaterhouseCoopers LLP as a Senior Associate from 2006-2011 as a member of the PwC’s Health Industries Advisory Services Biomedical Strategy Group. At PwC she specialized in identifying clinical trial operational efficiencies and regulatory compliance issues associated with clinical research in the life sciences, pharma or academic medical center space. Nicole has worked in the research setting at several top biopharmaceutical companies in Cambridge, the Massachusetts General Hospital and Florida State University. She holds a Master of Science in Biological Science from Florida State University as well as a Master of Business Administration from Boston University.


Board of Directors


Timothy P. Coleman, Ph. D., MBA

Cofounder CEO and President, Director

Tim Coleman is a chemist, biophysicist, inventor, philanthropist, and entrepreneur. He serves as the CEO of Nemucore Medical Innovations (nemucore.com) and as volunteer President of the Mending Minds Foundation (mminds.org). Tim is passionate about improving the health of people suffering from cancer and diseases of the brain. To this end he has co-founded organizations to help advance humanity’s collective ability to mitigate the harmful effects of these health conditions. His professional research efforts focus on the development of: innovative nanomedicines; immune programming platforms; a precision brain mapping system; targeted magnetic resonance imaging probes; precision small molecule therapeutics; and companion diagnostics based on system biology principles.

Tim believes many cancers are driven by the dysregulation of biology associated with non-genetic changes to a cell’s basic operating system. He is a proponent for identifying and clinical use of non-genetic changes as biomarkers that drive chemotherapeutic resistance in the battle to improve cancer outcomes. His team of precision medicine experts are developing small molecule therapeutics that use an RNA biomarker. This RNA biomarker measures the relative strength of a “network effect” of proteins involved in drug resistance and sensitivity to a key pathway responsible for malignant cell division. This system biology approach to understanding disease biology is also applicable to diseases of the brain.

Diseases of the brain including those associated with neuro-inflammation are driven by dysregulation of neuronal- or immuno-biology are one of the most sophisticated challenges of modern medicine. Today most diseases of the brain are diagnosed through clinical exclusion rather than direct molecular or cellular testing. Tim hopes to change this antiquated paradigm as he and his team are working in to develop a precision brain mapping system to accurately track diseases of the brain over time. They have developed an integrated nanomedicine brain magnetic resonance imaging system that uses paramagnetic nanoparticles to selectively bind to unique neurons in the brain. At current sensitivity, the system can map changes in a brain at the level of 20-50 cells and is designed to track structural changes in unique neurons over time. To achieve such high sensitivity, Tim and the team invented precisely targeted- paramagnetic nanoparticles that cross the blood brain barrier and tightly bind targeted neurons providing near-cellular level resolution. To analyze at this resolution, Tim and his team created an integrated data analysis software package that can analyze a single subject or be scaled to cohort level analysis. Tim is pursuing the development of the system to identify structural changes in populations of neurons to more quickly assess response to therapeutic intervention brain diseases.

Tim believes there is significant medical benefit to proactively intervening in the endocannabinoid system to mitigate diseases of the brain and peripheral nervous system. To demystify the endocannabinoid system and bring solid clinical science to the field, Tim and his team are pursuing a first ever double arm, placebo controlled, genomically-enabled, cannabinoid-based medicine clinical trial for the alleviation of chemotherapy induced peripheral neuropathy. The trial design and associated systems are being created to develop rigorous standards for testing cannabinoid-based medicines.

As an entrepreneur he enjoys the process of venture creation and has had his share of heartbreaking failures, including: BioCache Pharmaceuticals, Boston Electronic Application Market (BEAN), and Blue Ocean Biomanufacturing. True to his values, in 2018, Tim co-founded the Mending Minds Foundation to become the leading organization for the development of awareness, diagnostics, and treatments for a devastating disorder, childhood post infection neuroimmune disorders (CPIND). This neuroimmune disorder primarily affects children between the age of 3-15 and is routinely mis-diagnosed. If left untreated, it robs a child of their childhood or worse.

Always an athlete who loves to compete, Tim has become an avid runner and ultra- event competitor. He competes in 3-4 events annually using his participation to raise money for pediatric hematology oncology and breast cancer research. His personal goal is to run all six major marathons. He has authored numerous scientific papers, abstracts and patents. Tim lives in Wellesley, Massachusetts with his amazing wife, their high-energy daughter and loving dog Summer.


James Farinholt, Jr

Director
Chairman of the Nomination and Governance Committee

Mr. Farinholt has had an extensive career in both the private and public sectors of finance and investments. Most recently he served as a founding partner at Tall Oaks Capital Partners, a regional venture capital fund focused on early stage information technology and life sciences companies in the mid-Atlantic U.S. During the 1990s, he directed numerous business development activities at Virginia Commonwealth University where he served both as Rector and later as Assistant to the President for economic development. In conjunction with his promotion of the commercialization of scientific discoveries at the University, he initiated and oversaw several start-ups; and among them was Allos Therapeutics, Inc. which he co-founded and that went public in March 2000.

His earlier years in finance included roles as an executive officer in investment banking for small and medium-sized businesses at J. P. Morgan Chase in New York and Wheat First Union and Galleher & Company in Richmond, Virginia. Among the many companies for whom he managed their public offerings was Owens & Minor, Inc. the largest distributor of medical & surgical supplies in the U.S. Jim was appointed the company’s first independent director where he served on the Executive Committee as well as compensation, finance and strategic planning committees for the maximum term allowed under the company’s corporate policies.


Doug Bailey, MS MBA

Director
Chairman of the Compensation Committee

Mr. Bailey has held numerous leadership positions over nearly 40 years and is the co-founder of American Bailey Corporation (ABC), a closely held private equity firm of which he has been President since 1984 and Chief Executive Officer since 1996. He began his career as a mechanical engineer with Foster-Miller, Inc. in Waltham, MA. In 1978 he joined Corning, Inc. where he held a variety of positions in manufacturing and marketing prior to founding ABC. He was a founding director of VideoStar Connections, Inc., a successful satellite communications start-up company now part of Sony Electronics. Mr. Bailey also founded American Bailey Ventures (ABV), which has made venture capital investments in early-stage businesses, including Endocyte.

He has also served as CEO of a number of companies previously affiliated with ABC or ABV through acquisition or investment.

Currently, Mr. Bailey is Chairman, President and Chief Executive Officer of Fuel Tech, Inc. (NASDAQ:FTEK), which is engaged in the worldwide development, commercialization and application of state-of-the-art proprietary technologies for air pollution control, process optimization, and advanced engineering services. These technologies enable customers to produce both energy and processed materials in a cost-effective and environmentally sustainable manner. He has been a director of Fuel Tech since 1998 and has overall responsibility for the strategic, operational and management performance of the Company.

Mr. Bailey is also a director of GNP Management Corporation, the general partner of Great Northern Properties L.P. (GNP), co-owned by American Bailey Mining, L.P. and the principals of Quintana Minerals Corporation. GNP is a private partnership that is the largest holder of coal reserves (20 billion tons), behind only that of the U.S. Federal Government. Certain of GNP’s properties were placed in a master limited partnership, Natural Resource Partners L.P. (NYSE:NRP), prior to NRP going public.

Mr. Bailey holds a B.S., a M.S. and an Engineer’s degree, all in Mechanical Engineering from Massachusetts Institute of Technology, and an M.B.A. from Harvard Business School. He has served on the MIT Corporation Development Committee since 1998 and is the current Co-Chair of the New York Metro Region. He also was the r ecent Chair of the Annual Fund Board and a member of the MIT Alumni Association Board of Directors. He has led classmates through four reunion gift campaign, three of which were record breaking for MIT. Through his service at MIT he was named the recipient of the Henry B. Kane ’24 Award in 2003 and the Marshall B. Dalton ’15 Award in 2009. In 2012 he received the Bronze Beaver Award, the highest honor that MIT bestows upon any one of its more than 127,000 current member Alumni Association. Established in 1955, this award has been given to only 305 alumni.

As his pastime, Mr. Bailey is a competitive ballroom dancer at the Open level and regularly participates in competitions throughout the US. He and his wife, Sara, reside in Westport, CT.


Bryan Costantino, MS MBA, MPA

Director
Chairman of the Audit Committee

Bryan was a partner at PricewaterhouseCoopers for 25 years. He is also the co-founder and practice leader of a healthcare advisory practice which is now a greater than a billion dollar business. The practice consults on operations, strategy, regulatory and compliance issues for the payor, provider and Life Science Industries.


Dr. Michael Seiden, MD Ph. D.

Director And Chair of the Clinical Advisory Committee

Dr. Seiden currently serves as Senior Vice President and Chief Medical Officer of McKesson Specialty Health and U.S. Oncology, where he is responsible for bringing the assets of McKesson to a 1000-member cancer physician community conducting clinical research, and various quality and performance initiatives and enhancing the delivery of high-quality, evidence-based care. In this role, he is also responsible for maximizing collaborative efforts between pharmaceutical and biotechnology partners and manufacturers to generate improved patient outcomes and value for all stakeholders in the dynamic environment of drug development and launch. Prior to joining McKesson, Dr. Seiden served as the Chief Executive Officer and President of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital. Under his leadership, Fox Chase merged with Temple University Health System in 2012. Previously, Dr. Seiden was a practicing oncologist at Massachusetts General Hospital, where he served as Chief of the Clinical Research Unit, Cancer Center Division, and as Associate Professor in Medicine at Harvard University. At Massachusetts General Hospital, he launched its first-ever gynecologic cancer research initiative, which was later extended to partner affiliates Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Beth Israel Hospital to become one of the largest gynecological cancer research programs in the country. In 1995, Dr. Seiden was named Chair of the Clinical Research Committee for the Gynecologic Cancer Program within the Dana Farber / Harvard Cancer Center. He has been a practicing oncologist for more than 20 years.


Walter Ogier

Director

Mr. Ogier has more than thirty years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies and gene therapies. Following receipt of a BA (chemistry) from Williams College and an MBA from the Yale School of Management, he served nearly a decade with Baxter Healthcare Corporation in marketing and business development roles supporting the global adoption of bone marrow and adult stem cell transplantation before joining Aastrom Biosciences, where he served as VP Marketing and supported the company’s successful IPO in 1997. He was subsequently President and CEO of Eligix (sold to BioTransplant in 2001), Genetix Pharmaceuticals (renamed bluebird bio, Nasdaq: BLUE), and he was President/CEO and co-founder of Acetylon Pharmaceuticals (sold to Celgene in 2016) and of Regenacy Pharmaceuticals (spun out of Acetylon at the time of the Celgene acquisition). Along with being a Director of Nemucore Medical Innovations, Mr. Ogier currently serves as a director of Regenacy Pharmaceuticals Thetis Pharmaceuticals, Biothera Pharmaceuticals, and Katahdin Pharmaceuticals.


Clinical Advisors


Michael Seiden, M.D. PH.D.

Director And Chair of the Clinical Advisory Committee

Dr. Seiden currently serves as Senior Vice President and Chief Medical Officer of McKesson Specialty Health and U.S. Oncology, where he is responsible for bringing the assets of McKesson to a 1000-member cancer physician community conducting clinical research, and various quality and performance initiatives and enhancing the delivery of high-quality, evidence-based care. In this role, he is also responsible for maximizing collaborative efforts between pharmaceutical and biotechnology partners and manufacturers to generate improved patient outcomes and value for all stakeholders in the dynamic environment of drug development and launch. Prior to joining McKesson, Dr. Seiden served as the Chief Executive Officer and President of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital. Under his leadership, Fox Chase merged with Temple University Health System in 2012. Previously, Dr. Seiden was a practicing oncologist at Massachusetts General Hospital, where he served as Chief of the Clinical Research Unit, Cancer Center Division, and as Associate Professor in Medicine at Harvard University. At Massachusetts General Hospital, he launched its first-ever gynecologic cancer research initiative, which was later extended to partner affiliates Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Beth Israel Hospital to become one of the largest gynecological cancer research programs in the country. In 1995, Dr. Seiden was named Chair of the Clinical Research Committee for the Gynecologic Cancer Program within the Dana Farber / Harvard Cancer Center. He has been a practicing oncologist for more than 20 years.